| Uppsala, Sweden, February 13, 2007
Gyros completes five new sales of its Gyrolab®
protein quantification platform
Gyros announced today that it has completed the separate sales
of five Gyrolab® microfluidic system platforms to Merck, Biogen-Idec
and a third, unnamed company, all in the USA, and to NovImmune and
Serono in Europe. |
| Gyros microfluidic platform consists of Gyrolab
Bioaffy® compact disk (CD) microlaboratories (facilitating miniaturized
and integrated protein quantification applications) and Gyrolab
Workstation (a fully automated system for running Gyrolab Bioaffy
CDs). Together they provide a simple to use, precisely controlled
solution for processing hundreds of samples in parallel at nanoliter
scale. Scientists are able to use immunoassays with a very broad
measurement range to generate more information from less sample,
improving both productivity and efficiency.
|
|
Commenting
on the recent sales, Gyros CEO, Jan Würtz, said, “2006
was a successful year for Gyros. Following sales earlier in 2006
to CAT and AstraZeneca, these five new sales mean that we are really
starting to extend our customer base. We will be looking to continue
this trend through 2007, as more and more companies recognize that
our microfluidic technology can provide them with significant advantages
over traditional methods, like ELISA.”
|
About Gyros AB
Gyros is the leader in the miniaturization and integration of laboratory
applications through its proprietary microfluidics platform, Gyrolab
CD (compact disc) microlaboratory. Gyros delivers simple to use,
precisely controlled solutions for processing hundreds of samples
in parallel, generating more information from less sample and improving
lab productivity and efficiency.
Application-specific microlaboratories use a modular design offering
the potential to run different applications on a single instrument
and to create customized solutions. The company is currently focused
on two market segments: quantitative protein analysis for research,
drug discovery and development applications; and, in vitro
diagnostics for medical applications. Gyros has 50 employees working
at its headquarters and European sales office in Uppsala, Sweden
and its sales office in the USA.
For further information, visit www.gyros.com
or contact:
Jan Würtz, President and CEO, Gyros AB
Tel: +46 (0)18 566 400
Mobile: +46 (0)70 592 5670
jan.wurtz@gyros.com
Christina Burtsoff Asp, VP Marketing, Gyros AB
Tel: +46 (0)18 566 404
Mobile: +46 (0)70 666 1642
christina.asp@gyros.com
------------------------------------------------------------------------------------------------
Statements in this press release that are not strictly historical
may be forward-looking and include risks and uncertainties. Therefore,
though based on Gyros’ current expectations, it should be
duly noted that a variety of factors could cause actual results
and experiences to differ materially from what is herein expressed.
Risks and uncertainties include, but are not limited to, risks associated
with the management of growth and international operations (including
effects of currency fluctuations), variability of operating results,
unforeseen changes in the diagnostic and pharmaceutical markets,
market competition, rapid or unexpected changes in technologies,
fluctuations in product demand, difficulties to successfully develop,
adapt, produce or commercialize products, the ability to identify
and develop new products and to differentiate products from those
of competitors, as well as various legal hazards.
------------------------------------------------------------------------------------------------
|
